
-
Xencor Inc NASDAQ:XNCR Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Currently, 20 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of proteins resulting in new mechanisms of therapeutic action.
Location: 111 W Lemon Ave, California, 91016-2809, United States | Website: www.xencor.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
471.1M
Cash
497.8M
Avg Qtr Burn
-50.55M
Short % of Float
12.24%
Insider Ownership
1.22%
Institutional Own.
-
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Obexelimab (CD19) Details Lupus nephritis | Phase 3 Update | |
Plamotamab (CD20xCD3) Details Autoimmune disease, Rheumatoid arthritis | Phase 1/2 Initiation | |
Plamotamab (CD20xCD3) Details Non-Hodgkin lymphoma, Chronic lymphocytic leukemia, B-cell malignancies | Phase 1 Data readout | |
XmAb808 + pembrolizumab Details Solid tumor/s, Prostate cancer | Phase 1 Data readout | |
XmAb541 (CLDN6 x CD3) Details Ovarian cancer, Solid tumor/s | Phase 1 Data readout | |
XmAb819 (ENPP3 x CD3) Details Renal cell carcinoma | Phase 1 Data readout | |
XmAb942 Details Inflammatory bowel disease | Phase 1 Data readout | |
XmAb662 (IL12-Fc) Details Cancer, Solid tumor/s | Phase 1 Update | |
XmAb657 Details Autoimmune disease | Phase 1 Initiation | |
XmAb564 (IL-2-Fc) Details Autoimmune disease, Psoriasis, Atopic dermatitis | Phase 1a Update | |
Tidutamab (SSTR2xCD3) Details Cancer, Neuroendocrine tumor, Gastrointestinal stromal tumors | Failed Discontinued | |
Vudalimab (XmAb®717) (PD-1 x CTLA-4) Details Cancer, Non-small cell lung carcinoma | Failed Discontinued | |
Vibecotamab (CD123xCD3) Details Acute myeloid leukemia | Failed Discontinued | |
Vudalimab (XmAb®717) (PD-1 x CTLA-4) Details Renal cell carcinoma, Cancer, Prostate cancer | Failed Discontinued |